ArticleAnnals of medicine and surgery (2012)2026
The clinical effectiveness and safety of imiquimod versus podophyllotoxin in the topical treatment of condylomata acuminata: a systematic review and meta-analysis.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Imiquimod (IMQ) and podophyllotoxin (PDX) are two of the most common self-applied topical therapies for condyloma acuminatum. This review aims to directly compare their clinical effectiveness and safety profiles. Materials and methods: Records from two databases and two trial registers were screened for eligibility. The Mantel-Haenszel method was used for statistical analysis, using a fixed- or random-effects model depending on the calculated heterogeneity. Results: Five studies, two RCTs and three cohorts, were included. There was no statistically significant difference in the clinical effectiveness (RR = 0.98; 95% CI: 0.85-1.13; Conclusions: IMQ has comparable clinical effectiveness, more frequent adverse effects in adults, and less frequent adverse effects in children compared to PDX. Additionally, IMQ's lower wart recurrence may suggest a potential benefit in vaccinated individuals. Thus, IMQ may be slightly better than PDX in these populations, which warrants further research. Nevertheless, the utilized studies had small sample sizes and inadequate power to draw reasonable conclusions (low certainty).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.